Pilot Project 3: Contribution of Racial Disparity towards the Early Development of Pancreatic Cancer

试点项目 3:种族差异对胰腺癌早期发展的贡献

基本信息

  • 批准号:
    10006214
  • 负责人:
  • 金额:
    $ 11.3万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2018
  • 资助国家:
    美国
  • 起止时间:
    2018-09-17 至 2023-08-31
  • 项目状态:
    已结题

项目摘要

ABSTRACT: PILOT PROJECT Pancreatic ductal adenocarcinoma (PDAC) is the fourth most lethal cancer in the USA and is predicted to become the second most deadly cancer in the country by 2030. Blacks display an overall significantly greater age adjusted incidence and mortality rate from PDAC compared to Whites. Recognized risk factors for PDAC while at a higher prevalence in Blacks than Whites, does not account for the increased incidence and mortality from PDAC in Blacks, suggesting a biological explanation for the observed differences. The process of acinar ductal metaplasia (ADM) precedes PDAC precursor lesion formation. Since ADM is the earliest known precursor lesion for PDAC, acinar to ductal transdifferentiation is a key phase in the initiation of pancreatic cancer. We hypothesize that Blacks undergo ADM to a greater degree than Whites and that genetic as well as epigenetic factors account for this disparity. Specific Aim 1 will investigate the degree of in vitro ADM quantitatively using tissue samples from human pancreata of heathy donors obtained from pancreatic islet procurement centers. Non-islet fractions containing the primary, human pancreatic acini will be cultured and functionality will be demonstrated by inducing ADM in vitro. The duct formation doubling time and fold change in expression of acinar and ductal genes between Black and White donors will determine if ADM is enhanced in Blacks. Expression arrays will be used to identify the top genetic drivers of ADM in Blacks and Whites. Promoter DNA methylation will determine if epigenetic changes are responsible for the change in gene expression between Blacks and Whites. Specific Aim 2 will perform a genetic association study to identify SNPs in the genetic drivers of ADM using nested, case-control cohorts of PDAC data. Successful completion of this project will establish that racial disparities exist for the ability of pancreatic acini to undergo ADM. We will have also identified a gene expression signature that will characterize the ADM process by race as well as genetic and epigenetic factors that drive ADM in Blacks.
摘要:试点项目 胰腺导管腺癌(PDAC)是美国第四大致命性癌症,预计 到2030年成为该国第二大致命癌症。黑人总体上表现出更大的 与白人相比,年龄调整后的PDAC发病率和死亡率。公认的PDAC危险因素 虽然黑人的患病率高于白人,但这并不是发病率和死亡率增加的原因 来自黑人的PDAC,为观察到的差异提出了生物学解释。腺泡形成的过程 导管化生(ADM)先于PDAC前驱病变形成。因为ADM是已知最早的前体 对于PDAC来说,腺泡到导管的转分化是胰腺癌发生的关键阶段。我们 假设黑人比白人经历ADM的程度更大,并且遗传和表观遗传 造成这种差异的因素是多方面的。特异靶1将定量研究ADM的体外程度 取自胰岛采购中心的健康供者的人胰腺组织样本。 含有原发的人胰腺腺泡的非胰岛部分将被培养,功能将被 通过体外诱导ADM证实。腺泡形成倍增时间和折叠变化的研究 黑人和白人捐赠者之间的导管基因将决定黑人的ADM是否得到增强。表达式 阵列将被用来识别黑人和白人ADM的顶级遗传驱动因素。启动子DNA甲基化 将确定表观遗传变化是否导致黑人和黑人之间基因表达的变化 白色的。特定目标2将进行遗传关联研究,以确定ADM遗传驱动因素中的SNPs 使用PDAC数据的嵌套病例对照队列。这个项目的成功完成将建立起种族 胰腺腺泡细胞对ADM的耐受性存在差异。我们还将鉴定出一种基因表达 将通过种族以及驱动的遗传和表观遗传因素来表征ADM过程的签名 《黑衣行政官》。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

THOMAS D. SCHMITTGEN其他文献

THOMAS D. SCHMITTGEN的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('THOMAS D. SCHMITTGEN', 18)}}的其他基金

R21 MPI microRNA directed therapy for treating early stage pancreatic cancer
R21 MPI microRNA 定向疗法治疗早期胰腺癌
  • 批准号:
    10577609
  • 财政年份:
    2023
  • 资助金额:
    $ 11.3万
  • 项目类别:
Project 3 ADM
项目3 ADM
  • 批准号:
    10762126
  • 财政年份:
    2018
  • 资助金额:
    $ 11.3万
  • 项目类别:
miRNA Biomarkers for Hepatocellular Carcinoma Associated with Viral Hepatitis
病毒性肝炎相关肝细胞癌的 miRNA 生物标志物
  • 批准号:
    8520269
  • 财政年份:
    2012
  • 资助金额:
    $ 11.3万
  • 项目类别:
miRNA Biomarkers for Hepatocellular Carcinoma Associated with Viral Hepatitis
病毒性肝炎相关肝细胞癌的 miRNA 生物标志物
  • 批准号:
    8364566
  • 财政年份:
    2012
  • 资助金额:
    $ 11.3万
  • 项目类别:
Real-time PCR expression profiling of microRNA
microRNA 的实时 PCR 表达谱
  • 批准号:
    7137111
  • 财政年份:
    2006
  • 资助金额:
    $ 11.3万
  • 项目类别:
Real-time PCR expression profiling of microRNA
microRNA 的实时 PCR 表达谱
  • 批准号:
    7632039
  • 财政年份:
    2006
  • 资助金额:
    $ 11.3万
  • 项目类别:
Real-time PCR expression profiling of microRNA
microRNA 的实时 PCR 表达谱
  • 批准号:
    7596042
  • 财政年份:
    2006
  • 资助金额:
    $ 11.3万
  • 项目类别:
Real-time PCR expression profiling of microRNA
microRNA 的实时 PCR 表达谱
  • 批准号:
    7808845
  • 财政年份:
    2006
  • 资助金额:
    $ 11.3万
  • 项目类别:
Micro RNA Expression and Cancer
微小RNA表达与癌症
  • 批准号:
    6764682
  • 财政年份:
    2004
  • 资助金额:
    $ 11.3万
  • 项目类别:
Micro RNA Expression and Cancer
微小RNA表达与癌症
  • 批准号:
    6895843
  • 财政年份:
    2004
  • 资助金额:
    $ 11.3万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了